A board-certified veterinary oncologist will serve as a strategic adviser to Sonoma Pharmaceuticals as the company prepares to roll out a veterinary-exclusive formulation of its Microcyn product line.
Chelsea Tripp, DVM, MS, DACVIM, will focus on veterinarian outreach to support the anticipated November 2017 launch of MicrocynVS, a topical skin, wound, ear and eye medication. She will address Japanese veterinarians during a stop at the University of Tokyo in November, the company reported.
Dr. Tripp, founder of Bridge Animal Referral Center, also will assist with clinical studies of Sonoma Pharmaceuticals’ patented Microcyn Technology as it relates to resistant infections in animal oncology.
Bridge Animal Referral Center, an Edmonds, Washington, cancer treatment hospital, “has already deployed Microcyn-based topical products in a variety of settings for our treatment protocols, and the results to date in wound care are extremely favorable,” she said.
The new MicrocynVS line will contain 190 parts per million of the active ingredient hypochlorous acid, or free available chlorine — 65 percent more than what is in MicrocynAH, the retail version.
Sonoma Pharmaceuticals, formerly known as Oculus Innovative Sciences, is based in Petaluma, California.